{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:19:17Z","timestamp":1794932357131,"version":"4.9.1"},"reference-count":106,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1,4]]},"abstract":"<jats:p>CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic origin. CD38 is a transmembrane glycoprotein with ectoenzymatic activity, and also functions as a receptor and adhesion molecule. Altogether, this has triggered the development of several CD38 antibodies including daratumumab (fully human), isatuximab (chimeric), and MOR202 (fully human). CD38 antibodies have pleiotropic mechanisms of action including Fc-dependent immune-effector mechanisms, direct apoptotic activity, and immunomodulatory effects by the elimination of CD38+ immune-suppressor cells. CD38-targeting antibodies are generally well tolerated and induce partial response or better in \u223c30% of heavily pretreated MM patients as monotherapy. Based on their distinct mechanisms of action, favorable toxicity profile, and single-agent activity, CD38 antibodies are attractive partners in combination regimens. Indeed, deep responses and prolonged progression-free survival can be achieved in relapsed\/refractory MM patients when CD38 antibodies are combined with immunomodulatory agents or proteasome inhibitors. Infusion-related reactions, which typically occur during the first infusion, are the most frequent adverse events. Attention should also be paid to the interference of CD38 antibodies with certain laboratory assays, which may complicate response evaluation and blood compatibility testing. Several studies are currently examining the role of CD38-based therapies in newly diagnosed and high-risk smoldering MM. Furthermore, CD38 antibodies are currently also under investigation in other hematologic malignancies, including acute lymphoblastic leukemia, natural killer\/T-cell lymphoma, and acute myeloid leukemia, as well as in solid tumors.<\/jats:p>","DOI":"10.1182\/blood-2017-06-740944","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T15:25:19Z","timestamp":1510154719000},"page":"13-29","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":448,"title":["CD38 antibodies in multiple myeloma: back to the future"],"prefix":"10.1182","volume":"131","author":[{"given":"Niels W. C. J.","family":"van de Donk","sequence":"first","affiliation":[{"name":"Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Malavasi","sequence":"additional","affiliation":[{"name":"Laboratory of Immunogenetics, Department of Medical Sciences and"},{"name":"Center for Experimental Research and Medical Studies (CeRMS), University of Turin, Turin, Italy; and"},{"name":"Department of Transplantation Immunology, University Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111823211118800_B1","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1158\/1078-0432.CCR-14-3190","article-title":"CD38-targeted immunochemotherapy in refractory multiple myeloma: a new horizon","volume":"21","author":"Laubach","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111823211118800_B2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1073\/pnas.77.3.1588","article-title":"Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage","volume":"77","author":"Reinherz","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111823211118800_B3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0092-8674(81)90441-4","article-title":"Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10","volume":"23","author":"Terhorst","year":"1981","journal-title":"Cell"},{"issue":"1","key":"2019111823211118800_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"issue":"3","key":"2019111823211118800_B5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111823211118800_B6","doi-asserted-by":"crossref","first-page":"e1279723","DOI":"10.1080\/23723556.2017.1279723","article-title":"Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer","volume":"4","author":"Crowell","year":"2017","journal-title":"Mol Cell Oncol"},{"issue":"suppl 2","key":"2019111823211118800_B7","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jaci.2004.04.040","article-title":"Methodologic advancements in the study of airway smooth muscle","volume":"114","author":"Kotlikoff","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"3-4","key":"2019111823211118800_B8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2119\/molmed.2008.00108","article-title":"CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus","volume":"15","author":"Horenstein","year":"2009","journal-title":"Mol Med"},{"issue":"6","key":"2019111823211118800_B9","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.celrep.2012.10.018","article-title":"NAADP mediates insulin-stimulated glucose uptake and insulin sensitization by PPAR\u03b3 in adipocytes","volume":"2","author":"Song","year":"2012","journal-title":"Cell Reports"},{"issue":"3","key":"2019111823211118800_B10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.4049\/jimmunol.145.3.878","article-title":"CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells","volume":"145","author":"Alessio","year":"1990","journal-title":"J Immunol"},{"issue":"3","key":"2019111823211118800_B11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"issue":"1","key":"2019111823211118800_B12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J Immunol"},{"issue":"7","key":"2019111823211118800_B13","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood-2007-07-101600","article-title":"Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse","volume":"111","author":"Mu\u00f1oz","year":"2008","journal-title":"Blood"},{"issue":"5136","key":"2019111823211118800_B14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.8235624","article-title":"Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38","volume":"262","author":"Howard","year":"1993","journal-title":"Science"},{"issue":"40","key":"2019111823211118800_B15","doi-asserted-by":"crossref","first-page":"33693","DOI":"10.1074\/jbc.R500012200","article-title":"Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling","volume":"280","author":"Lee","year":"2005","journal-title":"J Biol Chem"},{"issue":"7","key":"2019111823211118800_B16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood-2013-02-483511","article-title":"Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity","volume":"122","author":"Cagnetta","year":"2013","journal-title":"Blood"},{"key":"2019111823211118800_B17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fimmu.2017.00305","article-title":"Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche","volume":"8","author":"Chillemi","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"2019111823211118800_B18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V77.5.1071.1071","article-title":"Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody","volume":"77","author":"Stevenson","year":"1991","journal-title":"Blood"},{"issue":"9","key":"2019111823211118800_B19","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood.V84.9.3017.3017","article-title":"Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma","volume":"84","author":"Goldmacher","year":"1994","journal-title":"Blood"},{"issue":"3","key":"2019111823211118800_B20","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"2019111823211118800_B21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"issue":"3","key":"2019111823211118800_B22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J Immunol"},{"issue":"21","key":"2019111823211118800_B23","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","article-title":"Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79 [abstract]","volume":"124","author":"Lammerts van Bueren","year":"2014","journal-title":"Blood"},{"issue":"17","key":"2019111823211118800_B24","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111823211118800_B25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"issue":"22","key":"2019111823211118800_B26","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood.V128.22.4521.4521","article-title":"High-parameter mass cytometry (CyTOF) evaluation of relapsed\/refractory multiple myeloma (MM) Pts (Pts) treated with daratumumab supports immune modulation as a novel mechanism of action [abstract]","volume":"128","author":"Adams","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2019111823211118800_B27","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111823211118800_B28","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.24781","article-title":"Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: an adjusted treatment comparison","volume":"92","author":"Usmani","year":"2017","journal-title":"Am J Hematol"},{"issue":"13","key":"2019111823211118800_B29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"2019111823211118800_B30","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"2019111823211118800_B31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111823211118800_B32","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","article-title":"Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib","volume":"21","author":"Nijhof","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111823211118800_B33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2019111823211118800_B34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/cpt.577","article-title":"Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed\/refractory multiple myeloma","volume":"101","author":"Xu","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"2019111823211118800_B35","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V128.22.1149.1149","article-title":"Open-label, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO) [abstract]","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111823211118800_B36","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/blood.V128.22.1152.1152","article-title":"A phase I\/IIa study of the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma [abstract]","volume":"128","author":"Raab","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111823211118800_B37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V126.23.509.509","article-title":"A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed\/refractory multiple myeloma [abstract]","volume":"126","author":"Martin","year":"2015","journal-title":"Blood"},{"issue":"suppl 15","key":"2019111823211118800_B38","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/JCO.2016.34.15_suppl.8005","article-title":"Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"34","author":"Richter","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111823211118800_B39","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2019111823211118800_B40","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"20","key":"2019111823211118800_B41","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-12-3676","article-title":"Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance","volume":"19","author":"de Haart","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111823211118800_B42","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.3324\/haematol.2015.139667","article-title":"Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance","volume":"101","author":"de Haart","year":"2016","journal-title":"Haematologica"},{"issue":"21","key":"2019111823211118800_B43","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1182\/blood.V124.21.2126.2126","article-title":"KIR and HLA genotypes influence clinical outcome in multiple myeloma patients treated with SAR650984 (anti-CD38) in combination with lenalidomide and dexamethasone [abstract]","volume":"124","author":"Marra","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111823211118800_B44","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/cells4030520","article-title":"NAD+-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model","volume":"4","author":"Horenstein","year":"2015","journal-title":"Cells"},{"issue":"21","key":"2019111823211118800_B45","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1182\/blood.V124.21.4729.4729","article-title":"SAR 650984, a therapeutic anti-CD38 monoclonal antibody, blocks CD38-CD31 interaction in multiple myeloma [abstract]","volume":"124","author":"An","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111823211118800_B46","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1182\/blood.V126.23.1849.1849","article-title":"Generation and characterization of microvesicles after daratumumab interaction with myeloma cells [abstract]","volume":"126","author":"Chillemi","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111823211118800_B47","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2014-10-569244","article-title":"Fc\u03b3-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments","volume":"125","author":"Taylor","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2019111823211118800_B48","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111823211118800_B49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood.V122.21.284.284","article-title":"SAR650984, a CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies: data from a dose-escalation phase I study [abstract]","volume":"122","author":"Martin","year":"2013","journal-title":"Blood"},{"issue":"suppl","key":"2019111823211118800_B50","doi-asserted-by":"crossref","first-page":"8574","DOI":"10.1200\/jco.2015.33.15_suppl.8574","article-title":"A phase I\/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM) [abstract]","volume":"33","author":"Raab","year":"2015","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111823211118800_B51","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1182\/blood.V126.23.4244.4244","article-title":"Treatment of ex vivo expanded NK cells with daratumumab F(ab\u2019)2 fragments protects adoptively transferred NK cells from daratumumab-mediated killing and augments daratumumab-induced antibody dependent cellular toxicity (ADCC) of myeloma [abstract]","volume":"126","author":"Cherkasova","year":"2015","journal-title":"Blood"},{"key":"2019111823211118800_B52","author":"Casneuf"},{"issue":"3","key":"2019111823211118800_B53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bjh.13776","article-title":"Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach","volume":"174","author":"Alici","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111823211118800_B54","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies","volume":"1","author":"van der Veer","year":"2011","journal-title":"Blood Cancer J"},{"issue":"2","key":"2019111823211118800_B55","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"van der Veer","year":"2011","journal-title":"Haematologica"},{"issue":"suppl 15","key":"2019111823211118800_B56","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1200\/jco.2015.33.15_suppl.8588","article-title":"Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide [abstract]","volume":"33","author":"Boxhammer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111823211118800_B57","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1182\/blood.V124.21.5712.5712","article-title":"Synergistic in vitro activity of MOR202, a human CD38 antibody, in combination with pomalidomide [abstract]","volume":"124","author":"Endell","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111823211118800_B58","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood.V126.23.2203.2203","article-title":"Lenalidomide enhances MOR202 dependent macrophage-mediated effector functions via the vitamin D pathway [abstract]","volume":"126","author":"Bruns","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2019111823211118800_B59","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111823211118800_B60","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood.V128.22.1151.1151","article-title":"Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of Pollux [abstract]","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111823211118800_B61","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood.V128.22.246.246","article-title":"Evaluation of minimal residual disease (MRD) in relapsed\/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone [abstract]","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"key":"2019111823211118800_B62","volume-title":"Clin Lymphoma Myeloma Leuk","author":"San-Miguel"},{"issue":"22","key":"2019111823211118800_B63","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V128.22.4531.4531","article-title":"Daratumumab in combination with lenalidomide plus dexamethasone induces clonality increase and T-cell expansion: results from a phase 3 randomized study (POLLUX) [abstract]","volume":"128","author":"Chiu","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2019111823211118800_B64","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"2019111823211118800_B65","volume-title":"Clin Lymphoma Myeloma Leuk","author":"Chatterjee"},{"key":"2019111823211118800_B66","volume-title":"Clin Lymphoma Myeloma Leuk","author":"Chari"},{"issue":"22","key":"2019111823211118800_B67","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1182\/blood.V128.22.2123.2123","article-title":"Preliminary results from a phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma [abstract]","volume":"128","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111823211118800_B68","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/blood.V128.22.2105.2105","article-title":"Critical analysis on the mechanism of action (MoA) of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma (MM) [abstract]","volume":"128","author":"Moreno","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111823211118800_B69","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood.V126.23.3015.3015","article-title":"MOR202, a human anti-CD38 monoclonal antibody, mediates potent tumoricidal activity in vivo and shows synergistic efficacy in combination with different antineoplastic compounds [abstract]","volume":"126","author":"Boxhammer","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2019111823211118800_B70","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V128.22.1150.1150","article-title":"Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of castor [abstract]","volume":"128","author":"Mateos","year":"2016","journal-title":"Blood"},{"issue":"suppl 15","key":"2019111823211118800_B71","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2017.35.15_suppl.8006","article-title":"Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status [abstract]","volume":"35","author":"Weisel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111823211118800_B72","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood.V128.22.2111.2111","article-title":"Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple myeloma [abstract]","volume":"128","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"2019111823211118800_B73","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8000","article-title":"Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study [abstract]","author":"Jakubowiak","year":"2017","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111823211118800_B74","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab","volume":"129","author":"Garc\u00eda-Guerrero","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2019111823211118800_B75","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3324\/haematol.2014.117531","article-title":"Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide","volume":"100","author":"Nijhof","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"2019111823211118800_B76","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"issue":"suppl 7S","key":"2019111823211118800_B77","article-title":"CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1\/PD-L1 axis [abstract]","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111823211118800_B78","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2019111823211118800_B79","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood.V126.23.1829.1829","article-title":"Management of infusion-related reactions following daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius) [abstract]","volume":"126","author":"Voorhees","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2019111823211118800_B80","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V128.22.2142.2142","article-title":"Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma [abstract]","volume":"128","author":"Chari","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111823211118800_B81","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1515\/cclm-2015-0888","article-title":"Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)","volume":"54","author":"van de Donk","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"2019111823211118800_B82","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"15","key":"2019111823211118800_B83","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.clinbiochem.2016.07.016","article-title":"Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay","volume":"49","author":"Rosenberg","year":"2016","journal-title":"Clin Biochem"},{"issue":"12","key":"2019111823211118800_B84","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/leu.2015.290","article-title":"Clarification of the definition of complete response in multiple myeloma","volume":"29","author":"Durie","year":"2015","journal-title":"Leukemia"},{"issue":"22","key":"2019111823211118800_B85","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.V128.22.2063.2063","article-title":"Overcoming the interference of daratumumab with immunofixation electrophoresis (IFE) using an industry-developed Dira test: hydrashift 2\/4 daratumumab [abstract]","volume":"128","author":"Caillon","year":"2016","journal-title":"Blood"},{"key":"2019111823211118800_B86","article-title":"Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood [published online ahead of print 21 September 2016]","author":"Murata","journal-title":"Clin Biochem"},{"issue":"12","key":"2019111823211118800_B87","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion"},{"issue":"6 Pt 2","key":"2019111823211118800_B88","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"issue":"6 Pt 2","key":"2019111823211118800_B89","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"issue":"22","key":"2019111823211118800_B90","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood-2016-11-749432","article-title":"Daratumumab (anti-CD38) induces loss of CD38 on red blood cells","volume":"129","author":"Sullivan","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019111823211118800_B91","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21307\/immunohematology-2019-005","article-title":"Use of standard laboratory methods to obviate routine dithiothreitol treatment of blood samples with daratumumab interference","volume":"33","author":"Lintel","year":"2017","journal-title":"Immunohematology"},{"issue":"11","key":"2019111823211118800_B92","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1111\/trf.13267","article-title":"Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma","volume":"55","author":"Hannon","year":"2015","journal-title":"Transfusion"},{"issue":"3","key":"2019111823211118800_B93","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMc1515969","article-title":"Interference of new drugs with compatibility testing for blood transfusion","volume":"375","author":"Murphy","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111823211118800_B94","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMc1613868","article-title":"Daratumumab and blood-compatibility testing","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111823211118800_B95","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood.V126.23.3571.3571","article-title":"Outcomes and management of red blood cell transfusions in multiple myeloma patients treated with daratumumab [abstract]","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2019111823211118800_B96","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2016-06-722496","article-title":"First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis","volume":"128","author":"Sher","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2019111823211118800_B97","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V128.22.4525.4525","article-title":"Hematologic responses and cardiac organ improvement in patients with heavily pretreated cardiac immunoglobulin light chain (AL) amyloidosis receiving daratumumab [abstract]","volume":"128","author":"Kaufman","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111823211118800_B98","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-15-2095","article-title":"The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia","volume":"23","author":"Matas-C\u00e9spedes","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2019111823211118800_B99","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJMc1605684","article-title":"Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma","volume":"375","author":"Hari","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111823211118800_B100","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood.V128.22.3018.3018","article-title":"Drug resistance alters CD38 expression and in vitro response to daratumumab in waldenstrom macroglobulinemia cells [abstract]","volume":"128","author":"Paulus","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2019111823211118800_B101","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/blood.V124.21.2312.2312","article-title":"Anti-leukemic activity of daratumumab in acute myeloid leukemia cells and patient-derived xenografts [abstract]","volume":"124","author":"Dos Santos","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2019111823211118800_B102","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1182\/blood.V128.22.4819.4819","article-title":"Daratumumab is effective in the treatment of refractory post-transplant autoimmune hemolytic anemia: a pediatric case report [abstract]","volume":"128","author":"Tolbert","year":"2016","journal-title":"Blood"},{"key":"2019111823211118800_B103","volume-title":"J Allergy Clin Immunol","author":"Blankestijn","year":"2017"},{"issue":"12","key":"2019111823211118800_B104","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","article-title":"Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma","volume":"35","author":"van Beurden-Tan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111823211118800_B105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.V124.21.176.176","article-title":"An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma [abstract]","volume":"124","author":"Moreau","year":"2014","journal-title":"Blood"},{"key":"2019111823211118800_B106","volume-title":"Clin Lymphoma Myeloma Leuk","author":"Richardson"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/1\/13\/1367755\/blood740944.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/1\/13\/1367755\/blood740944.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T02:21:26Z","timestamp":1693189286000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/1\/13\/107710\/CD38-antibodies-in-multiple-myeloma-back-to-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-06-740944","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,4]]}}}